Table 1 Differences in admission SAPS II and SOFA score, plasma suPAR levels between survivors and non-survivors, septic shock and non-septic shock patients and differences in amputation rates in high vs. low suPAR (above or below 7.4 ng/mL) NSTI patients.

From: SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study

 

N (%)

Mortality, N (%)

SAPS II (95% CI)

SOFA (95% CI)

Died within 90 days

Yes

43 (22)

 

62 (58–67)

10.9 (9.9–11.9)

No

157 (78)

 

41 (39–43)

7.2 (6.7–7.7)

Septic shock

Yes

79 (40)

29 (37)

52 (49–56)

10 (9.4–10.7)

No

121 (60)

14 (12)

42 (39–44)

6.7 (6.1–7.2)

 

N (%)

suPAR (ng/mL)

95% CI

P-value

    

<0.001

Yes

43 (22)

11

7.8–14.2

 

No

157 (78)

6.1

2.9–9.3

 

Septic shock

   

<0.001

Yes

79 (40)

9.2

7–11.2

 

No

121 (60)

5.8

3.6–8

 
 

No amputation

Amputation

Total

suPAR ≤ 7.4 ng/mL

118 (90%)

13 (10%)

131

suPAR ≥ 7.4 ng/mL

51 (74%)

18 (26%)

69

  1. Data are means (95% CI) or numbers (%). SAPS II Simplified Acute Physiology Score II. SOFA Sequential Organ Failure Score. suPAR soluble urokinase-type plasminogen activator receptor. NSTI necrotizing soft-tissue infections.
  2. Pearson’s Chi-squared test with Yates’ continuity correction, Χ2 = 7.8, p-value = 0.005. Optimal cutoff for predicting Day-90 mortality of 7.4 ng/mL was found via the suPAR ROC curve. Welch’s t-test, p-value < 0.001.
Back to article page